27/09/2026 Aumseqa EU Authorization Revoked Following Regulatory Challenge; Hansoh Pursues Refiling Aumseqa EU Authorization Revoked Following Regulatory Challenge; Hansoh Pursues Refiling (Ref) Hansoh Pharma announced that the European Commission has revoked the EU marketing authorization for lung cancer drug Aumseqa (aumolertinib mesylate tablets; EGFR-TKI) Decision stems from a regulatory procedural issue related to EU data protection requirements and is not associated wit

Highlights from the CHMP Dec 2025 Meeting are out! New Medicines 💊 Conditional marketing authorisation of ImmunityBio, Inc.'s nogapendekin alfa inbakicept (Anktiva: IL-15 superagonist complex) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours 💊 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.’s aumolertinib (Aumseq